Esperion Therapeutics (NASDAQ:ESPR) Receives Buy Rating from HC Wainwright

HC Wainwright restated their buy rating on shares of Esperion Therapeutics (NASDAQ:ESPR) in a research report sent to investors on Tuesday,Benzinga reports. The firm currently has a $16.00 price target on the biopharmaceutical company’s stock.

A number of other analysts have also weighed in on the company. Cantor Fitzgerald began coverage on Esperion Therapeutics in a report on Tuesday, December 17th. They set an “overweight” rating and a $8.00 target price for the company. JMP Securities reiterated a “market outperform” rating and set a $7.00 price objective on shares of Esperion Therapeutics in a report on Thursday, January 23rd. StockNews.com lowered Esperion Therapeutics from a “buy” rating to a “hold” rating in a report on Friday, November 15th. Needham & Company LLC reiterated a “buy” rating and set a $6.00 price objective on shares of Esperion Therapeutics in a report on Friday, December 13th. Finally, The Goldman Sachs Group started coverage on Esperion Therapeutics in a research note on Wednesday, December 18th. They issued a “neutral” rating and a $4.00 target price for the company. One analyst has rated the stock with a sell rating, two have given a hold rating and four have assigned a buy rating to the company. According to data from MarketBeat, the company has an average rating of “Hold” and an average target price of $6.75.

Esperion Therapeutics Stock Down 3.8 %

Esperion Therapeutics stock opened at $1.79 on Tuesday. The business has a fifty day moving average of $2.31 and a two-hundred day moving average of $2.12. The firm has a market cap of $352.70 million, a P/E ratio of -2.80 and a beta of 1.01. Esperion Therapeutics has a twelve month low of $1.58 and a twelve month high of $3.94.

Institutional Investors Weigh In On Esperion Therapeutics

A number of institutional investors have recently modified their holdings of ESPR. The Manufacturers Life Insurance Company acquired a new stake in shares of Esperion Therapeutics during the 2nd quarter valued at about $159,000. SG Americas Securities LLC raised its position in shares of Esperion Therapeutics by 105.9% during the 3rd quarter. SG Americas Securities LLC now owns 77,049 shares of the biopharmaceutical company’s stock valued at $127,000 after buying an additional 39,635 shares during the period. Boomfish Wealth Group LLC raised its position in shares of Esperion Therapeutics by 17.1% during the 3rd quarter. Boomfish Wealth Group LLC now owns 34,997 shares of the biopharmaceutical company’s stock valued at $58,000 after buying an additional 5,102 shares during the period. Traphagen Investment Advisors LLC purchased a new stake in shares of Esperion Therapeutics during the 3rd quarter valued at approximately $27,000. Finally, Versor Investments LP purchased a new stake in shares of Esperion Therapeutics during the 3rd quarter valued at approximately $44,000. 47.39% of the stock is currently owned by institutional investors and hedge funds.

About Esperion Therapeutics

Esperion Therapeutics, Inc, a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease who require additional lowering of LDL-C.